BioPharma Resources

Drug Trial Radar · NCT07183306

A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection

A Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HT-101 Injection and/or HT-102 Injection in Patients With Chronic Hepatitis B Virus Infection

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

86

Actual

Start

Dec 30, 2024

Primary completion

Aug 24, 2027

Study completion May 3, 2028

Sponsor

Sponsor type
Industry
First posted
Sep 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is A multicenter, open-label, partial multiple-ascending doses phase1b/2 in which participants with chronic hepatitis B virus (HBV) infection will receive HT-101 and/or HT-102 and be assessed for safety, tolerability, Pharmacokinetics, and Pharmacodynamics. Approximately 86 patients with chronic hepatitis B infection were planned to be recruited. Among them, Group A and Group AA received HT-101 injection, administered once every 4 weeks (Q4W), at least for 24 weeks. Group B received HT-102 injection, administered Q4W for 24 weeks and sequential dosed with HT-101 for another 24 weeks. Groups C, D, and E received HT-101 injection combined with HT-102 injection, administered once every 4 weeks for 24weeks. During the study period, all subjects received nucleoside (acid) analogues (NAs) treatment.

Conditions

  • Chronic Hepatitis B

Interventions

  • HT-101Drug

    HT-101 given by subcutaneous injection.

  • HT-102Drug

    HT-102 given by subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinically significant abnormalitiesTime frame: From enrollment to the end of treatment at up to 60 weeks
  2. Incidence of adverse events (AEs) and serious adverse events (SAEs)Time frame: From enrollment to the end of treatment at up to 60 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Ditan Hospital Capital Medical University

    Beijing, Beijing Municipality, China

  • Xiamen Hospital of Traditional Chinese Medicine

    Xiamen, Fujian, China

  • Guangzhou Eighth People's Hospital, Guangzhou Medical University

    Guangzhou, Guangdong, China

  • Nanfang Hospital

    Guangzhou, Guangdong, China

  • Qingyuan People's Hospital

    Qingyuan, Guangdong, China

  • Shanghai Public Health Clinical Center

    Shanghai, Shanghai Municipality, China

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.